COVID training Modules

INDIAN COUNCIL OF MEDICAL RESEARCH DEPARTMENT OF HEALTH RESEARCH Advisory on Use of Rapid Antigen Detection Test for COVID-19 Dated: 14th June 2020 Background: 1. Real time RT-PCR is the gold standard frontline test for diagnosis of COVID19. Various open and closed RT-PCR platforms (Open systems RT-PCR machines, TrueNat and CBNAAT) are currently being used for COVID19 diagnosis in India. All these platforms require specialized laboratory facilities in-terms of equipment, biosafety & biosecurity. Minimum time taken for the test varies between different systems with a minimum of 2-5 hours including the time taken for sample transportation. These specifications limit the widespread use of the RT-PCR test and also impedes quick augmentation of testing capacity in various containment zones and hospital settings. 2. In view of this, there is urgent need of a reliable point-of-care rapid antigen detection test with good sensitivity and specificity for early detection of t

S ummary of literature - key points - updated 20th June 2020 Favipiravir -20/06/2020  Approved (accelerated approval ) by DCGI for use in Mild/Moderate cases of Covid-19. Dosage 1800mg BD on day 1 followed by 800mg BD for 14 days. Tablet available as 200mg (Fabiflu) at the cost of 103 Rs per tablet, total pills 122 at the cost of 12500 Rs for whole course of therapy. RNAdependent RNA polymerase inhibitor like Remdesivir. Informed consent to be taken before administration. Contraindicated in pregnancy because of teratogenic effects seen in mice, though experience for usage in Influenza is good. Suggested to do UPT in child-bearing age group women before starting. Need to stop the drug for one week before conceiving.         Can be given in Diabetes, interaction with Repaglinide.         Not to be given in severe kidney dysfunction with GFR below 30 ml/min         Not to be given in Liver dysfunction         Effect of combination with other antiviral drugs not known.